Nhng ai c nh mang thai nn ct thuc t nht 3 thng k t ln s dng sau cng
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
Journal of Cosmetic Dermatology, June 2019, pages 728-737 4
Watch out for GMOs and glyphosate exposure
For patients on broader longevity or optimization protocols, GHK-Cu injections may also be combined with NAD+ therapy, BPC-157, or other peptides depending on their clinical goals
Your symptoms The specific issues youre hoping to improve can also indicate which therapy will target your needs
